BLSM — BlossomHill Therapeutics
Median target
$31
calls from the last 12 months
Implied return
+15.6%
median target vs. price
Coverage
4 analysts · 4 calls
updated in the last 12 months
Consensus
4/0/0+4 net
Buy / Hold / Sell
Which analysts are behind BLSM's consensus?
See every current rating, price target and the analysts' track records for BlossomHill Therapeutics — plus the full analyst rankings, firm analytics and screener.
The consensus above reflects 4 analysts with calls on BLSM updated in the last 12 months. Implied return is the move implied if the consensus target were hit. These are forward-looking predictions, not realized returns. Per-analyst ratings and track records are a Premium feature.
BLSM elsewhere on AnalystEdge
The most recent congressional, executive-branch and insider filings matched to this ticker. Matched by ticker symbol — occasional mismatches are possible. Not investment advice.
Trending today: not in any of today's trending tables (Gaining attention, Losing attention, Most followed)
| Date | Source | Who | Action | Detail | Amount |
|---|---|---|---|---|---|
| 2026-08-10 | Insiders | Orbimed Advisors Llc +1Director | Insider purchase | 625.0K sh @ $16.00 | $10.0M |
| 2026-08-10 | Insiders | Gordon Carl LDirector | Insider purchase | 625.0K sh @ $16.00 | $10.0M |
| 2026-08-10 | Insiders | Chen Bihua +5Director | Insider purchase | 312.5K sh @ $16.00 | $5.0M |
| 2026-08-10 | Insiders | Schmid John P.Director | Insider purchase | 6.0K sh @ $16.00 | $96K |
| 2026-08-10 | Insiders | Liptak Vincent PaulGeneral Counsel | Insider purchase | 2.2K sh @ $16.00 | $35K |
| 2026-08-10 | Insiders | Keyes Jason AChief Financial Officer | Insider purchase | 700 sh @ $16.00 | $11K |
| 2026-08-07 | Insiders | Liptak Vincent PaulGeneral Counsel | Insider purchase | 2.5K sh @ $15.80 | $40K |
More: insider activity · executive branch · trending